‘Cancer deaths will double in four years’


With the dubious distinction of being called the 'kharra' capital, Nagpur has the highest 15.7% males who are suffering from mouth cancerin Vidarbha. Females are also not far behind with 5.1% cases, the third highest, who are victims of mouth cancer caused mainly due to tobacco chewing. These are the figures Rashtrasant Tukdoji Regional Cancer Hospital has arrived at after collecting data in the region.


Addressing a press conference on Thursday, Dr BK Sharma, director of RST Regional Cancer Hospital and Research Centre (RST RCH), said, "According to the data, around 80% of mouth cancer deaths occur due to tobacco chewing. Going by the trend, it is quite possible that the number of deaths by cancer will double in the coming four years."


Meanwhile, the hospital will conduct a continuing medical education (CME) programme on 'Head and neck cancers — recent updates' in association with Cancer Relief Society, Indian Medical Association and other organizations on Sunday. A discussion on latest pathological methods on diagnosis of head and neck cancer to its management by surgery, radiology and medical oncology will be held.


A special workshop on 'Advance radiotherapy techniques in head and neck cancers' has also been organized for medical physicists. Anil D'cruz and Prathmesh Pai from Mumbai and Moni Kuriakose from Bengaluru, besides others, will address the conference.

Source:http://timesofindia.indiatimes.com/city/nagpur/cancer-deaths-will-double-in-four-years/articleshow/59168573.cms

Comments

Post a Comment

Popular posts from this blog

EMA Recommends Extension of Indications for Ramucirumab

The European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product ramucirumab (Cyramza). The marketing authorisation holder for this medicinal product is Eli Lilly Nederland B.V. The CHMP adopted a new indication as follows: “Cyramza monotherapy is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma who have a serum alpha fetoprotein (AFP) of ≥ 400 ng/ml and who have been previously treated with sorafenib”. For information, the full indications for Cyramza will be as follows : Gastric cancer Cyramza in combination with paclitaxel is indicated for the treatment of adult patients with advanced gastric cancer or gastro-oesophageal junction adenocarcinoma with disease progression after prior platinum and fluoropyrimidine chemotherapy. Cyramza monotherapy is indicated for the treatm
Read more

Dr. Hootie Warren takes helm of Fred Hutch Global Oncology

The goal of Fred Hutch Global Oncology, says Dr. Hootie Warren, its newly named head, is "to figure out how we can adapt the incredibly exciting work that’s done here so that it can benefit people all around the world.” Photo by Robert Hood / Fred Hutch News Service Immunotherapy researcher and oncologist  Dr. Edus H. Warren  works on the front lines of a revolution. In his 24 years at Fred Hutchinson Cancer Research Center, Warren, who goes by the nickname “Hootie,” has contributed to jaw-dropping discoveries in harnessing the immune system to fight cancer. Today  immunotherapy  is considered the most exciting advance in decades, joining surgery, radiation therapy and chemotherapy as a fourth pillar of cancer care. Now, as the new head of  Fred Hutch Global Oncology , he is set to lead a revolution that could be just as transformative: improving cancer care in sub-Saharan Africa and other regions that do not always have access to even the first three pillars. Fred
Read more

Bristol-Myers Squibb and Clovis Oncology Announce a Broad Clinical Collaboration to Evaluate Combination of Opdivo (Nivolumab) and Rubraca® (Rucaparib) in Phase 2 and Pivotal Phase 3 Clinical Trials in Multiple Tumor Types

Image
Bristol-Myers Squibb Company  (NYSE:BMY) and  Clovis Oncology, Inc. (Nasdaq:CLVS) announced the companies have entered into a clinical collaboration agreement to evaluate the combination of Bristol-Myers Squibb’s immunotherapy  Opdivo   and Clovis Oncology’s poly (ADP-ribose) polymerase (PARP) inhibitor  Rubraca  in pivotal phase 3 clinical trials in: Advanced ovarian cancer : First-line maintenance treatment study to evaluate  Rubraca  +  Opdivo ,  Rubraca ,  Opdivo  and placebo in newly diagnosed patients with stage III/IV high-grade ovarian, fallopian tube, or primary peritoneal cancer who have completed platinum-based chemotherapy. Advanced triple-negative breast cancers  (TNBC): First-line maintenance treatment study to evaluate  Rubraca  +  Opdivo ,  Rubraca ,  Opdivo  and chemotherapy in patients with stage IV or recurrent locally advanced inoperable TNBC associated with a homologous recombination deficiency (HRD). The collaboration will also include a Phase 2 study to e
Read more